Thomas Schmitt

8PUBLICATIONS
81CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 09, 2026
Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.

|Feb 04, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics.

Thomas M Schmitt, Kelsey Furiya, Cheryl Black

|Jan 03, 2026
A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands.

Shihong Zhang, Tzu-Hao Tang, Sinéad Kinsella

|May 08, 2025
Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.

Zackery A Ely, Zachary J Kulstad, Gurcan Gunaydin

|Sep 30, 2024
Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activity.

Jihoon William Lee, Emily Y Chen, Taylor Hu

|Feb 09, 2022
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.

Miranda C Lahman, Thomas M Schmitt, Kelly G Paulson

Pageof 2

Frequent Collaborators

5 joint publications

Aude G Chapuis

3 joint publications

Valentin Voillet

3 joint publications

Cecilia Yeung

2 joint publications

Anthony Rongvaux